Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (BCTX) generates frequent news flow as a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a strong focus on metastatic breast cancer. News about BriaCell often centers on clinical trial milestones, emerging efficacy and safety data, biomarker analyses, and platform advancements across its Bria-IMT™, Bria-OTS™, and Bria-OTS+™ programs.
Investors and researchers following BCTX news can track updates on the pivotal Phase 3 Bria-IMT trial in advanced metastatic breast cancer, including enrollment progress, interim analyses, and presentations at major scientific meetings such as the San Antonio Breast Cancer Symposium (SABCS®). Company releases describe survival outcomes, progression-free survival signals, and potential predictive biomarkers like neutrophil-to-lymphocyte ratio, delayed-type hypersensitivity responses, and Th1-biased cytokine signatures.
BriaCell’s news stream also highlights developments in its Bria-OTS and Bria-OTS+ off-the-shelf immunotherapy platforms. Announcements include clinical observations such as sustained complete resolution of lung metastasis in a metastatic breast cancer patient treated with Bria-OTS, as well as preclinical data showing robust innate and adaptive immune activation by Bria-OTS+ candidates Bria-BRES+™ and Bria-PROS+™ in breast and prostate cancer models.
Additional coverage includes corporate and pipeline updates from BriaPro Therapeutics Corp., BriaCell’s subsidiary, and its AI-driven collaboration with Receptor.AI to design isoform-selective kinase inhibitors. For those monitoring BCTX, this news page provides a centralized view of regulatory designations, trial recognitions in scientific publications, collaborative research announcements, and detailed scientific poster summaries. Regular visits can help readers follow how BriaCell’s immunotherapy platforms evolve from preclinical research through late-stage clinical evaluation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board. Dr. Ostrand-Rosenberg boasts over 40 years of experience in cancer immunology and has contributed significantly to the understanding of the immune response to cancer. Her notable research includes work on CD4+ T-helper lymphocytes and myeloid-derived suppressor cells. The collaboration aims to enhance BriaCell's pipeline of immunotherapies, particularly for advanced breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed Dr. Jane Gross to its Board of Directors. With over 30 years of biotech experience, Dr. Gross has held significant roles at various companies, emphasizing her expertise in cancer therapeutics. The Board hopes to leverage her insights to advance BriaCell's immunotherapy pipeline. Additionally, the company granted stock options to Dr. Gross and its Scientific Advisory Board. BriaCell also announced a contract with North Equities Corp. for marketing and investor engagement purposes, costing CAD$105,000.
BriaCell Therapeutics Corp. (BCTX, BCTXW) recognizes October as Breast Cancer Awareness Month, highlighting the ongoing need for effective breast cancer treatments. The company, with $57 million cash as of July 31, 2021, continues its targeted immunotherapy program, achieving a notable 12-month overall survival benefit in trials and resolving a severe tumor in a patient. Additionally, BriaCell has initiated a securities buyback program to enhance shareholder value. The company emphasizes its commitment to treating patients beyond mere statistics.
BriaCell Therapeutics Corp. (BCTX, BCTXW) announces significant advancements in its immunotherapy for advanced breast cancer. In a recent interview, CEO Dr. Bill Williams highlighted a partnership with ImaginAb to assess the safety and efficacy of their treatments. The board has expanded to include corporate finance expert Marc Lustig, and the company plans to utilize over $55 million in excess capital for share repurchases. Dr. Williams emphasized the need to align the company’s valuation with its clinical progress, addressing concerns regarding its current market valuation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has received approval from the TSX Venture Exchange for a normal course issuer bid (the “Buyback”). This allows the company to repurchase up to 1,341,515 common shares and 411,962 warrants over the next 12 months, starting September 28, 2021. This Buyback, managed by Independent Trading Group Inc., represents 10% of the public float as of September 21, 2021. The company assures that this initiative will not disrupt its growth plans in cancer immunotherapy and ongoing clinical trials.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bill Williams, President and CEO, is scheduled to speak at 1:15 PM ET on September 29. The event will be held virtually, and investors can register for a free spectator pass. BriaCell focuses on immunotherapies for advanced breast cancer, aiming to provide targeted treatment approaches. For more details, visit briacell.com.
BriaCell Therapeutics Corp. (BCTX, BCTXW) has authorized a repurchase program for up to 1,341,515 common shares and 411,962 warrants, representing 10% of the public float. With a cash balance of US$57 million as of July 31, 2021, the buyback is expected to enhance shareholder value. The Company is advancing its cancer immunotherapy pipeline, with key studies planned for 2022. The buyback will not interfere with BriaCell's growth initiatives in cancer treatments. Independent Trading Group will manage the repurchase program, which is subject to regulatory approvals.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced the appointment of Marc Lustig to its Board of Directors, effective September 1, 2021. Lustig, a significant shareholder with 10% ownership through L5 Capital Inc., brings extensive experience in corporate finance and pharmaceuticals. He aims to enhance the company's capital markets strategy. The Board also approved a grant of 100,000 options to Lustig at C$7.24 per share, vesting immediately, with proceeds intended for donation to the Cedars Cancer Foundation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference held virtually from September 13-15, 2021. Dr. William Williams, President & CEO, will outline the company's business during the presentation scheduled for September 13 at 7:00 A.M. (ET). Investors can access the presentation online through the provided link, with archived access for 90 days. BriaCell focuses on targeted immunotherapies for advanced breast cancer and is committed to innovative cancer management approaches.
BriaCell Therapeutics has entered into a multi-year, non-exclusive license agreement with ImaginAb to utilize its advanced CD8 ImmunoPET imaging technology for analyzing tumor-attacking CD8 T cells in breast cancer patients. This partnership supplements BriaCell's ongoing Phase I/IIa study and aims to enhance the assessment of safety and efficacy for its immunotherapy treatments. The collaboration is expected to accelerate drug development and improve patient care, with continued clinical doses and technical support from ImaginAb.